Since cancer has a very complex pathophysiology, existing
cancer
treatment strategies encounter several challenges such as the lack
of specificity/selectivity, induction of multidrug resistance, and
possible side effects/toxicity. A wide variety of organic, inorganic,
and hybrid nanosystems have been designed with unique magnetic, thermal,
mechanical, electrical, and optical properties for targeted cancer
therapy. These advanced nanosystems with enhanced bioavailability,
biocompatibility, and drug loading capacity have been developed for
targeted cancer therapy to reduce toxicity and improve the targeting
properties. In this context, challenges persist for their clinical
translational studies and enhancement of their therapeutic efficiency
as well as the optimization of synthesis conditions and large-scale
production. In addition, despite promising preclinical results, the
number of nanosystems available to patients is still very low, partly
due to a lack of understanding of the differences among animal model
species and humans that influence the behavior and functionality of
these nanosystems. Regarding this, organ-on-a-chip platforms can significantly
help in drug screening and delivery aspects in cancer/tumor cells
as well as cancer modeling research; the organs-on-chip approach can
also be helpful to analyze the cancer–immune cells interactions.
Future studies should focus on the exploration of multifunctional
nanosystems with synergistic chemo-photothermal, photothermal/photodynamic,
and cancer immunotherapeutic potentials as well as smart nanosystems
with theranostic capabilities. Herein, recent advancements pertaining
to the applications of advanced nanosystems for cancer therapeutics
are deliberated. Current obstacles and limitations hindering the application
from research to clinical uses are also discussed while providing
recommendations for a more efficient adoption of nanomaterials in
the treatment of cancers.